Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: This study aimed to evaluate the clinical efficacy of probiotic-based interventions in modulating the inflammatory response of periapical tissues and maintaining alveolar bone homeostasis following oral alveolar surgery.
Method: In this open-label, nonblinded trial, 80 patients undergoing alveolar surgery were randomised into an experimental group (n = 40) receiving postoperative Lactobacillus reuteri DSM 17938 probiotics (10 CFU/d) and a control group (n = 40) receiving standard care. Alveolar bone density was measured via cone-beam computed tomography (CBCT) at 1, 3, and 5 months postsurgery. Oral microbial diversity (16S rRNA sequencing) and inflammatory markers (IL-1β, TNF-α, IL-6) were analysed at 3 months.
Result: The experimental group demonstrated a 3.8% higher bone density than controls at all follow-ups (P < .05), alongside a 15.2% increase in microbial diversity (Shannon index, P < .05). Proinflammatory cytokines were significantly reduced (IL-1β: -18.5%; TNF-α: -22.1%; IL-6: -14.7%, P < .05). While the bone density improvement was modest, its statistical significance suggests potential clinical relevance for osseointegration. Probiotic supplementation attenuated inflammation and enhanced alveolar bone stability postsurgery. However, the nonblinded design limits generalizability.
Conclusion: Probiotic-based interventions with Lactobacillus reuteri effectively modulated the inflammatory response and enhanced alveolar bone homeostasis postalveolar surgery in this cohort. While promising, future double-blind trials with larger cohorts are needed to confirm these findings and explore broader translational applications in bone regeneration strategies.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12272125 | PMC |
| http://dx.doi.org/10.1016/j.identj.2025.100881 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Elinzanetant for the Treatment of Vasomotor Symptoms Associated With Menopause: A Phase 3 Randomized Clinical Trial.
JAMA Intern Med
September 2025
Bayer CC AG, Basel, Switzerland.
Importance: There is an unmet need for long-term, safe, effective, and hormone-free treatments for menopausal symptoms, including vasomotor symptoms (VMS) and sleep disturbances.
Objective: To evaluate the 52-week efficacy and safety of elinzanetant, a dual neurokinin-targeted therapy, for treating moderate to severe VMS associated with menopause.
Design, Setting, And Participants: OASIS-3 was a double-blind, placebo-controlled, randomized phase 3 clinical trial that was conducted at 83 sites in North America and Europe from August 27, 2021, to February 12, 2024, and included postmenopausal women aged 40 to 65 years who were seeking treatment for moderate to severe VMS (no requirement for a minimum number of VMS events per week).
Effects of Glucagon-Like Peptide-1 receptor agonists on bone health in people living with obesity.
Osteoporos Int
September 2025
Department of Rheumatology, Univ. Lille, CHU Lille, MABlab ULR 4490, 59000, Lille, France.
Medications like liraglutide 3.0 mg daily (Saxenda®; Novo Nordisk) and semaglutide 2.4 mg weekly (Wegovy®; Novo Nordisk), which are glucagon-like peptide-1 receptor agonists (GLP-1Ra), have been sanctioned for prolonged weight management in people living with obesity (PwO).
View Article and Find Full Text PDFIterative decomposition of water and fat with echo asymmetry and least-squares estimation (IDEAL-IQ) for evaluation of early bone mass changes in ageing osteoporosis patients.
Magn Reson Lett
May 2025
GE Healthcare, Beijing, 100176, China.
This study explored the application value of iterative decomposition of water and fat with echo asymmetry and least-squares estimation (IDEAL-IQ) technology in the early diagnosis of ageing osteoporosis (OP). 172 participants were enrolled and underwent magnetic resonance imaging (MRI) examinations on a 3.0T scanner.
View Article and Find Full Text PDFUncovering Overlapping Gene Networks and Potential Therapeutic Targets in Osteoporosis and COVID-19 Through Bioinformatics Analysis.
Int J Endocrinol
August 2025
Department of Geriatrics, Zhongshan Hospital Xiamen University, School of Medicine, Xiamen University, Xiamen 361000, Fujian, China.
Osteoporosis is a progressive bone disease characterized by reduced bone density and deterioration of bone microarchitecture, predominantly affecting the elderly population. The ongoing COVID-19 pandemic has introduced additional challenges in osteoporosis management, potentially due to systemic inflammation and direct viral impacts on bone metabolism. This study aims to identify common differentially expressed genes (DEGs) and key molecular pathways shared between osteoporosis and COVID-19, with the goal of uncovering potential therapeutic targets through bioinformatics analysis.
View Article and Find Full Text PDFDeep Learning Model for Osteoporosis Screening From Chest Radiographs: A Multicenter Analysis of External Robustness and Model Calibration.
Cureus
August 2025
Department of Orthopaedic Surgery, Teikyo University School of Medicine, Tokyo, JPN.
Osteoporosis is a common condition, and treatment can reduce the risk of fracture and extend healthy life expectancy, but most cases go undiagnosed and untreated. Dual-energy X-ray absorptiometry (DXA), the gold standard for diagnosing osteoporosis, is costly, time-consuming, and labor-intensive, with limited availability in low-resource settings and small clinics, so it is not suitable for screening for potential osteoporosis. To address this problem, in recent years, some studies have attempted to screen for osteoporosis by estimating DXA bone mineral density (BMD) from chest radiographs (CR), which are frequently used in daily clinical practice, by applying deep learning technology.
View Article and Find Full Text PDF